Knight Therapeutics, a pan-American (ex-U.S.) pharmaceutical company, repaid all amounts outstanding under its revolving credit facility with National Bank of Canada and a syndicate of lenders.
The credit facility provides borrowing capacity of up to $100 million, with an additional $100 million accordion feature subject to certain conditions. In June 2025, Knight drew $60 million from the credit facility to support the acquisition of Paladin. The company has repaid all outstanding amounts under the credit facility.
“Today marks the one-year anniversary of the Paladin transaction and we are proud that we have repaid within a year the credit we withdrew to finance the acquisition,” Arvind Utchanah, chief financial officer of Knight, said. “The repayment which was made within a year was funded by the strong cash flow generated by our business in Canada and Latin America. We appreciate the ongoing support of our financing partners, and with our revolving credit facility providing capacity of up to US$200 million, we remain well positioned to execute our long-term growth strategy.”
